Q3 10-Q: Going Concern, $6.2M Nine-Month Loss, Cash Through January 2027
LABT sits 45% above its 52-week low of $0.169 on light trading volume (0.3× avg).
Summary
Lakewood-Amedex reported a $6.17 million nine-month loss and said substantial doubt exists about its ability to continue as a going concern, with cash lasting only through January 2027 — while Nasdaq moves to delist the stock and share count has already more than doubled since September 30.
Key Events · Earnings and Guidance · LABT
-
Going Concern Warning Reiterated
Management concluded its plans do not alleviate substantial doubt about the company's ability to continue as a going concern, citing a $6,170,030 nine-month net loss and $3,714,859 of operating cash burn.
-
Cash Runway Ends January 2027
Cash and equivalents of $2,823,636 plus $500,000 of certificates of deposit are expected to fund operations only through January 2027, requiring new financing within about two months.
-
Share Count More Than Doubles Post-Quarter
Series C conversions raised common shares outstanding from 3,659,688 at September 30, 2026 to 8,950,088 by November 2, 2026; the remaining 127,097 preferred shares were then repurchased for $1,270,970 and cancelled.
-
Nasdaq Delisting Proceedings Pending
Nasdaq notified the company on November 10, 2026 that it intends to delist for trading below $1.00, with no compliance period available because of the June 22, 2026 1-for-10 reverse split; a hearing request would stay suspension.
Analysis · LABT · Life Sciences
Operationally the quarter was quiet, but the disclosure is severe. Lakewood-Amedex lost $6.17 million in the first nine months of 2026 against $3.10 million a year earlier, and management explicitly concluded that its plans do not alleviate substantial doubt about the company's ability to continue as a going concern. Cash of $2.82 million plus $0.5 million of certificates of deposit is expected to fund operations only through January 2027, so a financing must land within roughly two months. That need arrives while Nasdaq has already moved to delist the stock for trading below $1.00 and the company is ineligible for a normal compliance period because of its June 2026 1-for-10 reverse split. The Series C overhang was retired — 127,097 preferred shares repurchased for $1,270,970 on November 2, 2026 — but the cost was heavy: conversions lifted common shares outstanding from 3,659,688 at September 30 to 8,950,088 by November 2, 2026. The central risk is a capital raise into a delisting fight at a $0.245 share price.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LABT was trading at $0.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.17 to $98.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.